Exploration of Bromodomain Proteins as Drug Targets for Niemann–Pick Type C Disease
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125769 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Martina Parente und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science, Section Biomedical Science and Technology, University Roma Tre, Viale Marconi 446, 00146 Rome, Italy. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type C, Triazoles, Azepines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Telethon Foundation, Centre National de la Recherche Scientifique, Université de Strasbourg.
Abstract (Originalsprache)
Defects in lysosomal cholesterol handling provoke fatal disorders presenting neurovisceral symptoms with variable onset and life spans. A prime example is Niemann–Pick type C disease (NPCD), where cholesterol export from the endosomal–lysosomal system is impaired due to variants of either NPC intracellular cholesterol transporter 1 (NPC1) or NPC intracellular cholesterol transporter 2 (NPC2). Therapeutic options for NPCD are limited to palliative care and disease-modifying drugs, and there is a need for new treatments. Here, we explored bromodomain and extra-terminal domain (BET) proteins as new drug targets for NPCD using patient-derived skin fibroblasts. Treatment with JQ1, a prototype BET protein inhibitor, raised the level of NPC1 protein, diminished lysosomal expansion and cholesterol accumulation, and induced extracellular release of lysosomal components in a dose-, time-, and patient-dependent manner. Lastly, JQ1 enhanced and reduced cholesterol accumulation induced by pharmacologic inhibition of NPC1 and of histone deacetylase (HDAC) activity, respectively. Taken together, bromodomain proteins should be further explored as therapeutic drug targets for lysosomal diseases like NPCD, and as new components regulating lysosomal function and cholesterol metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Science, Section Biomedical Science and Technology, University Roma Tre, Viale Marconi 446, 00146 Rome, Italy.
- Institut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, Université de Strasbourg, 8 Allée du Général Rouvillois, 67000 Strasbourg, France.
- Department of Biosciences and Territory, University of Molise, Contrada Fonte Lappone s.n.c., 86090 Pesche, Italy.
- Neuroendocrinology Metabolism and Neuropharmacology Unit, IRCSS Fondazione Santa Lucia, Via del Fosso Fiorano 64, 00143 Rome, Italy.
ORCID-Profile: Martina Parente, Claudia Tonini, Sara Caputo, Stefano Leone, Marco Segatto, Frank W Pfrieger, Valentina Pallottini
Förderung
- Telethon Foundation
- Centre National de la Recherche Scientifique
- Université de Strasbourg
- Ara Parseghian Medical Research Fund
- Niemann-Pick Selbsthilfegruppe e.V.
- Together Strong Niemann-Pick foundation
- BILD Hilft e.V.
- Niemann–Pick Selbsthilfegruppe e.V.
Zitieren
APA
Parente, M., Barthelemy, A., Tonini, C., Caputo, S., Sacchi, A., Leone, S., Segatto, M., Pfrieger, F. W., & Pallottini, V. (2025). Exploration of Bromodomain Proteins as Drug Targets for Niemann–Pick Type C Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125769
Vancouver
Parente M, Barthelemy A, Tonini C, Caputo S, Sacchi A, Leone S, et al. Exploration of Bromodomain Proteins as Drug Targets for Niemann–Pick Type C Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125769
BibTeX
@article{Parente2025,
author = {Parente, Martina and Barthelemy, Amélie and Tonini, Claudia and Caputo, Sara and Sacchi, Alessandra and Leone, Stefano and Segatto, Marco and Pfrieger, Frank W and Pallottini, Valentina},
title = {Exploration of Bromodomain Proteins as Drug Targets for Niemann–Pick Type C Disease},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125769}
}
EUVIMED